# Chiome Bioscience

Source: https://onco.cc/companies/chiome-bioscience/  
OnCo record `chiome-bioscience` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Chiome Bioscience is a Japanese company that makes antibody medicines; its two clinical programmes target proteins on liver cancer and other solid tumours.

## Summary

Chiome Bioscience Inc. (4583.T) is a Tokyo company founded in 2005, according to the company, to commercialise the ADLib system, a monoclonal antibody generation technology developed with RIKEN. Its in-house clinical programmes are CBA-1205, an afucosylated (ADCC-enhanced) humanised antibody against DLK-1 in a first-in-human phase 1 study in advanced solid tumours, hepatocellular carcinoma, melanoma and paediatric cancer (NCT06636435), and CBA-1535, a Tribody T cell engager binding 5T4, CD3 and 5T4 in a first-in-human phase 1 study (NCT07016997). ADCT-701, an antibody-drug conjugate built on its LIV-1205 anti-DLK-1 antibody, is being studied by the US National Cancer Institute. Its first registered cancer trial, NCT06636435, was posted on ClinicalTrials.gov in October 2024, although the registry gives a study start date of June 2020, so the programme was in the clinic before it was registered there.

## Fields

- Kind: Company
- Last checked: 2026-10-29
- Also known as: Chiome Bioscience Inc.
- HQ: Tokyo
- Type: biotech
- Website: https://www.chiome.co.jp/en/
- Ticker: 4583.T

## Notes

- Listing (4583.T), founding date (8 February 2005) and Tokyo headquarters from the company's English overview page, read on 29 October 2026. Pipeline from the company's pipeline page, read the same day. No relation is made for DLK-1 or 5T4 because OnCo has no target records for them. No financing rows are recorded for this listed company.

## Sources

- Official website: https://www.chiome.co.jp/en/
- Company overview: https://www.chiome.co.jp/en/company/overview/
- Pipeline: https://www.chiome.co.jp/en/pipeline/
- ClinicalTrials.gov: phase 1 trial of CBA-1205 (NCT06636435): https://clinicaltrials.gov/study/NCT06636435
- ClinicalTrials.gov: phase 1 trial of CBA-1535 (NCT07016997): https://clinicaltrials.gov/study/NCT07016997

## Connected records

- cancers: [Hepatocellular carcinoma](https://onco.cc/cancers/hcc/)
- fronts: [Immunotherapy](https://onco.cc/fronts/immunotherapy/), [Targeted Therapy](https://onco.cc/fronts/targeted-therapy/)
- technologies: [Monoclonal antibodies](https://onco.cc/technologies/monoclonal-antibody/), [T-cell engagers (bispecific)](https://onco.cc/technologies/t-cell-engager/), [Trispecific antibodies](https://onco.cc/technologies/trispecific-antibodies/)

---
JSON: https://onco.cc/api/v1/entities/chiome-bioscience.json